(S)-3-chloro-5-(7-(2-((5-chloro-2-(3-methylmorpholino)pyridin-4-yl)amino)-2-oxoethyl)-3-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-hydroxybenzamide

ID: ALA5279982

Max Phase: Preclinical

Molecular Formula: C26H25Cl2N7O5

Molecular Weight: 586.44

This compound is available for customization.

Associated Items:

Bioactivity Summary Target Summary Assay Summary

Names and Identifiers

Canonical SMILES: C[C@H]1COCCN1c1cc(NC(=O)Cn2cc(-c3cc(Cl)c(O)c(C(N)=O)c3)c3c(=O)n(C)cnc32)c(Cl)cn1

Standard InChI: InChI=1S/C26H25Cl2N7O5/c1-13-11-40-4-3-35(13)20-7-19(18(28)8-30-20)32-21(36)10-34-9-16(22-25(34)31-12-33(2)26(22)39)14-5-15(24(29)38)23(37)17(27)6-14/h5-9,12-13,37H,3-4,10-11H2,1-2H3,(H2,29,38)(H,30,32,36)/t13-/m0/s1

Standard InChI Key: NDRFFOKFYGUOKD-ZDUSSCGKSA-N

Molfile:

 
     RDKit          2D

 40 44  0  0  0  0  0  0  0  0999 V2000
   -3.4291    0.5197    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7145    0.9320    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0026    0.5201    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0026   -0.3050    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7127   -0.7168    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4291   -0.3087    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2197   -0.5510    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7276    0.1166    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1984    0.7702    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9848    1.5673    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5682    2.1510    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3545    2.9455    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5572    3.1591    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0244    2.5796    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1843    1.7818    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8215    2.7932    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0351    3.5903    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.4050    2.2097    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3437    3.9562    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0061   -1.3480    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2090   -1.5616    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0044   -2.3586    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.8015   -2.5722    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3853   -1.9889    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1797   -2.2025    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3933   -2.9998    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.8138   -3.5816    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0160   -3.3727    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4325   -3.9562    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    2.7632   -1.6190    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.5497   -0.8220    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1331   -0.2385    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9302   -0.4521    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.1437   -1.2491    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5602   -1.8326    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3744   -0.9781    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7145    1.7571    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1437    0.9322    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9380    3.5290    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    1.7526   -0.6084    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  0
  3  2  1  0
  4  3  2  0
  5  4  1  0
  6  5  2  0
  1  6  1  0
  4  7  1  0
  7  8  1  0
  9  8  2  0
  3  9  1  0
 10  9  1  0
 11 10  2  0
 12 11  1  0
 13 12  2  0
 14 13  1  0
 15 14  2  0
 10 15  1  0
 14 16  1  0
 16 17  2  0
 16 18  1  0
 13 19  1  0
  7 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
 24 23  2  0
 25 24  1  0
 26 25  2  0
 27 26  1  0
 28 27  2  0
 23 28  1  0
 28 29  1  0
 30 25  1  0
 30 31  1  0
 32 31  1  0
 33 32  1  0
 34 33  1  0
 35 34  1  0
 30 35  1  0
 21 36  2  0
  2 37  2  0
  1 38  1  0
 12 39  1  0
 31 40  1  1
M  END

Associated Targets(Human)

BCL6 Tchem B-cell lymphoma 6 protein (838 Activities)

Discover Target: BCL6

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

KARPAS-422 (454 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Natural Product: No	Oral: No	Chemical Probe: No	Parenteral: No
Molecule Type:	Topical: No	First In Class: No	Black Box: No
Chirality: No	Availability: No	Prodrug: No

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 586.44	Molecular Weight (Monoisotopic): 585.1294	AlogP: 2.77	#Rotatable Bonds: 6
Polar Surface Area: 157.60	Molecular Species: ACID	HBA: 10	HBD: 3
#RO5 Violations: 1	HBA (Lipinski): 12	HBD (Lipinski): 4	#RO5 Violations (Lipinski): 2
CX Acidic pKa: 6.45	CX Basic pKa: 5.05	CX LogP: 2.81	CX LogD: 2.01
Aromatic Rings: 4	Heavy Atoms: 40	QED Weighted: 0.31	Np Likeness Score: -1.35

References

1. Mamai A, Chau AM, Wilson BJ, Watson ID, Joseph BB, Subramanian PR, Morshed MM, Morin JA, Prakesch MA, Lu T, Connolly P, Kuntz DA, Pomroy NC, Poda G, Nguyen K, Marcellus R, Strathdee G, Theriault B, Subramaniam R, Mohammed M, Abibi A, Chan M, Winston J, Kiyota T, Undzys E, Aman A, Austin N, Du Jardin M, Packman K, Phillippar U, Attar R, Edwards J, O'Meara J, Uehling DE, Al-Awar R, Privé GG, Isaac MB.. (2023) Discovery of OICR12694: A Novel, Potent, Selective, and Orally Bioavailable BCL6 BTB Inhibitor., 14 (2.0): [PMID:36793435] [10.1021/acsmedchemlett.2c00502]
2. Cardenas, Mariano G MG and 24 more authors. 2016-09-01 Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. [PMID:27482887]
3. Kamada, Yusuke Y and 11 more authors. 2017-05-25 Discovery of a B-Cell Lymphoma 6 Protein-Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based Approach. [PMID:28471657]
4. McCoull, William W and 33 more authors. 2017-05-25 Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors. [PMID:28485934]
5. Yasui, Takeshi T and 18 more authors. 2017-09-01 Discovery of a novel B-cell lymphoma 6 (BCL6)-corepressor interaction inhibitor by utilizing structure-based drug design. [PMID:28760529]
6. Guo, Weikai and 12 more authors. 2020-01-23 Synthesis and Biological Evaluation of B-Cell Lymphoma 6 Inhibitors of N-Phenyl-4-pyrimidinamine Derivatives Bearing Potent Activities against Tumor Growth. [PMID:31895575]
7. Bellenie, Benjamin R and 29 more authors. 2020-04-23 Achieving In Vivo Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders. [PMID:32275432]
8. Teng, Mingxing and 8 more authors. 2020-06-11 Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface. [PMID:32551010]

(S)-3-chloro-5-(7-(2-((5-chloro-2-(3-methylmorpholino)pyridin-4-yl)amino)-2-oxoethyl)-3-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-hydroxybenzamide

Names and Identifiers

Alternative Forms

Associated Targets(Human)

Molecule Features

Drug Indications

Mechanisms of Action

Calculated Properties

References

Source